In elderly patients diagnosed with acute myeloid leukemia (AML), standard remission induction therapy is generally not considered suitable due to the inability to tolerate treatment-related toxicities. In these patients, targeted therapies and novel agents are primarily preferred. One of the most frequently used regimens is the combination therapy of venetoclax and azacitidine.